H.C. Wainwright assumed coverage of Spruce Biosciences (SPRB) with a Buy rating and $220 price target The company is developing tralesinidase alfa enzyme replacement therapy for the treatment of Sanfilippo syndrome type B, the analyst tells investors in a research note. The firm sees potential for accelerated review. It believes TA-ERT could achieve peak sales of over $150M in the U.S. alone.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SPRB:
- Spruce Biosciences Appoints Keli Walbert as Director
- Spruce Biosciences Announces Board Resignation and Stock Repricing
- Biotech Alert: Searches spiking for these stocks today
- Spruce Biosciences upgraded to Outperform from Market Perform at Leerink
- Spruce Biosciences price target raised to $259 from $254 at Citizens JMP